TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
Promising Clinical Outcomes and Imminent FDA Approval Bolster Buy Rating for Humacyte's Bioengineered Vessel
Humacyte(HUMA.US) Director Sells US$6.61 Million in Common Stock
$Humacyte(HUMA.US)$ Director Dougan Brady W sold 1.5 million shares of common stock on Nov 18, 19, 20, 2024 at an average price of $4.4 for a total value of $6.61 million. This transaction involves
Form 144 | Humacyte(HUMA.US) Director Proposes to Sell 3.6 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 18, $HUMACYTE INC C/WTS (TO PUR COM)(HUMAW.US)$、$Humacyte(HUMA.US)$ Director AYABUDGE LLC intends to sell 811.17K shares of its common stock on Nov 18, with a total
Humacyte Price Target Maintained With a $12.00/Share by HC Wainwright & Co.